Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

A coating for an expandable portion of a catheter comprising a lipophilic matrix and a plurality of micro-reservoirs dispersed in the lipophilic matrix is disclosed. The plurality of micro-reservoirs comprises an active agent. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

A post-fabrication method for drug loading a medical device with an active pharmaceutical ingredient (API). Such medical devices can include a polymer matrix, where the polymer matrix, after exposure to a loading solution with the API, can exhibit a degree of swelling of the polymer matrix and/or a degree of swelling in which the polymer matrix increases in a dimension along an axis. Medical devices including a polymer matrix and an API are provided, where the API is loaded into the polymer matrix by adsorption and/or swelling after fabrication of the polymer matrix, wherein the medical device provides a substantially sustained release of the API for an extended period of time. The medical devices include intravaginal rings (IVR). Methods of treating a subject using the disclosed medical devices are also provided, including treating a subject with an IVR with one or more APIs loaded therein.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Active Energy Facilitated Drug Delivery platform for delivering therapeutics to biological tissue through electrical conductivity. This delivery method is comprised of an elastic alloy to encase a balloon or drug deposition, where the alloy acts to emit an electric field in aiding and actively allowing the pharmaceutical agent to have enhanced permeation, binding and internalization to cells and the biological matrix. A therapeutic agent is deposited onto a balloon to embody the drug deposition, reservoir whereby the electrical field facilitates the active transfer of a pharmaceutical agent to the target tissue is described.

A polymer hydrogel with a slow-release function, and a preparation method and use thereof are provided. The polymer hydrogel includes the following components in mass percentage contents: 0.01% to 15% of an active ingredient, 0.01% to 15% of an ion inhibitor, 0.01% to 1% of a crosslinking agent, 0.1% to 10% of a polymer resin, 10% to 35% of a solvent, 0.1% to 15% of a skin-touch regulator, 10% to 55% of deionized water, 0.1% to 3% of an appearance modifier, 0.01% to 1% of a crosslinking regulator, 0.01% to 1% of a preservative, and 0.01% to 5% of a transdermal absorption enhancer. The polymer hydrogel prepared by the present disclosure has excellent skin adaptability and skin permeability, long drug slow-release time, and excellent bioadhesion to the skin, and can be repeatedly peeled off without residue.